Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Equity Average (2018 - 2025)

Arcus Biosciences has reported Equity Average over the past 8 years, most recently at $533.5 million for Q4 2025.

  • Quarterly results put Equity Average at $533.5 million for Q4 2025, up 1.62% from a year ago — trailing twelve months through Dec 2025 was $533.5 million (up 1.62% YoY), and the annual figure for FY2025 was $558.0 million, up 17.85%.
  • Equity Average for Q4 2025 was $533.5 million at Arcus Biosciences, up from $492.5 million in the prior quarter.
  • Over the last five years, Equity Average for RCUS hit a ceiling of $819.5 million in Q1 2022 and a floor of $491.0 million in Q4 2023.
  • Median Equity Average over the past 5 years was $583.9 million (2021), compared with a mean of $608.8 million.
  • Biggest five-year swings in Equity Average: surged 283.01% in 2021 and later fell 27.58% in 2023.
  • Arcus Biosciences' Equity Average stood at $692.3 million in 2021, then fell by 2.07% to $678.0 million in 2022, then dropped by 27.58% to $491.0 million in 2023, then grew by 6.92% to $525.0 million in 2024, then grew by 1.62% to $533.5 million in 2025.
  • The last three reported values for Equity Average were $533.5 million (Q4 2025), $492.5 million (Q3 2025), and $540.0 million (Q2 2025) per Business Quant data.